Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures

Praxis Precision Medicines, Inc.

POWER1 study of vormatrigine in focal onset seizures did not meet primary success measure.
Secondary 50% response rate achieved; higher 30 mg dose showed more pronounced seizure reduction in second half.
Vormatrigine well-tolerated with <10% adverse event-related discontinuations; ~90% entered open-label extension.
Company pausing enrollment in POWER2 study to reassess vormatrigine program and potential modifications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.